$EVO News

Evotec SE (EVO) Q1 2026 Earnings Call Transcript

Evotec SE 2026 Q1 - Results - Earnings Call Presentation

Evotec Raises FY2026 Sales Guidance from $814.906M-$908.038M to $819.700M-$913.380M vs $870.860M Est

Evotec Q1 EPS $(0.40) Misses $0.08 Estimate, Sales $183.430M Miss $197.190M Estimate

Evotec Nominates Preclinical Development Candidate From Almirall Collaboration Targeting Immune-Mediated Inflammatory Skin Diseases

Evotec Receives Two Gates Foundation Grants Totalling $9.9M To Advance Novel Tuberculosis Drug Discovery And Clinical Combination Regimens

Evotec Names Claire Hinshelwood As CFO Effective May 1, Succeeding Paul Hitchin Who Departs For Personal Reasons

Evotec Names Claire Hinshelwood As CFO Effective May 1, Succeeding Paul Hitchin Who Departs For Personal Reasons

Correction: Evotec Reported Q4 Earnings On April 8

Evotec Sees FY2026 Sales $814.906M-$908.038M vs $957.470M Est

Evotec Q4 EPS $0.05 Beats $0.02 Estimate, Sales $294.879M Beat $253.350M Estimate

Just-Evotec Biologics Wins BARDA Project Agreement Valued At Up To $10M To Optimize Biomanufacturing Of Monoclonal Antibody Cocktail Targeting Ebola And Sudan Virus

Evotec Restructuring Aims To Improve Profitability After Transition Year

Evotec: What's Going On In 2026E And How To Value The Company

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket

Evotec (XTRA:EVT) Valuation Check After Recent Short Term Share Price Momentum

Has The Recent Rebound In Evotec (XTRA:EVT) Reset Market Expectations?

Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access

Just - Evotec Biologics Secures Gates Foundation Grant To Support AI-Driven Monoclonal Antibody Optimization